Vanda Pharmaceuticals (VNDA) Scheduled to Post Quarterly Earnings on Wednesday

Vanda Pharmaceuticals (NASDAQ:VNDA) will announce its earnings results after the market closes on Wednesday, May 2nd. Analysts expect the company to announce earnings of ($0.17) per share for the quarter.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings data on Wednesday, February 14th. The biopharmaceutical company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.08. The company had revenue of $44.28 million during the quarter, compared to analysts’ expectations of $44.00 million. Vanda Pharmaceuticals had a negative return on equity of 11.94% and a negative net margin of 9.43%. Vanda Pharmaceuticals’s revenue for the quarter was up 15.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.08 earnings per share. On average, analysts expect Vanda Pharmaceuticals to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

How to Become a New Pot Stock Millionaire

Vanda Pharmaceuticals stock opened at $14.60 on Wednesday. The firm has a market cap of $749.01, a P/E ratio of -41.71 and a beta of 1.13. Vanda Pharmaceuticals has a one year low of $11.90 and a one year high of $20.40.



A number of analysts recently commented on VNDA shares. Seaport Global Securities started coverage on Vanda Pharmaceuticals in a research report on Friday, January 19th. They set a “buy” rating and a $20.00 price objective for the company. BidaskClub raised Vanda Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, February 21st. Oppenheimer set a $27.00 price target on Vanda Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, February 15th. Zacks Investment Research raised Vanda Pharmaceuticals from a “sell” rating to a “buy” rating and set a $17.00 price target for the company in a report on Friday, April 20th. Finally, Jefferies Group reissued a “buy” rating and set a $20.00 price target on shares of Vanda Pharmaceuticals in a report on Tuesday, February 13th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $21.50.

In other news, insider Mihael Hristos Polymeropoulos sold 60,966 shares of the company’s stock in a transaction dated Thursday, March 1st. The stock was sold at an average price of $18.72, for a total value of $1,141,283.52. Following the completion of the transaction, the insider now owns 1,243,838 shares of the company’s stock, valued at $23,284,647.36. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO James Patrick Kelly sold 8,532 shares of the company’s stock in a transaction dated Thursday, March 1st. The stock was sold at an average price of $18.72, for a total value of $159,719.04. Following the completion of the transaction, the chief financial officer now directly owns 208,066 shares of the company’s stock, valued at approximately $3,894,995.52. The disclosure for this sale can be found here. Insiders have sold 78,023 shares of company stock valued at $1,460,591 in the last three months. 7.60% of the stock is currently owned by corporate insiders.

TRADEMARK VIOLATION WARNING: “Vanda Pharmaceuticals (VNDA) Scheduled to Post Quarterly Earnings on Wednesday” was originally reported by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be read at https://stocknewstimes.com/2018/04/25/vanda-pharmaceuticals-vnda-scheduled-to-post-quarterly-earnings-on-wednesday.html.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.

Earnings History for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply